Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
VESPER-2 is a 28-week Phase 2b clinical trial assessing the efficacy and tolerability of different weekly doses of MET-097i with or without titration. The trial enrolled the first participant in March ...
It's been just four days since the IPL 2025 began, but there's no dearth of young unknowns who continue to captivate the imagination of the audience.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback